



November 22, 2017

GW Pharmaceuticals to Present at Upcoming Investor Conferences

— 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 —

— Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on November 30, 2017 —

LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 12:00 p.m. ET at the Lotte New York Palace, New York, NY and at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 2:00 p.m ET at the Boston Harbor Hotel in Boston, MA.

A live audio webcast of the presentations will be available through GW's corporate website at www.gwpharm.com on the Investors section under Events & Presentations. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted an NDA to the FDA for the adjunctive treatment of LGS and Dravet syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioblastoma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc

Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570